{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:00:00Z","timestamp":1773370800874,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.clindermatol.2011.03.007","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T19:19:17Z","timestamp":1323371957000},"page":"34-37","source":"Crossref","is-referenced-by-count":66,"title":["Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)"],"prefix":"10.1016","volume":"30","author":[{"given":"Lawrence S.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2011.03.007_bb0005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archderm.1993.01680250060007","volume":"129","author":"Chan","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1172\/JCI116033","article-title":"Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease","volume":"90","author":"Domloge-Hultsch","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0020","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/sj.jid.5700465","article-title":"Antigen specificity in subsets of mucous membrane pemphigoid","author":"Rashid","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0025","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1523-1747.2003.12081.x","article-title":"Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta 4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model","volume":"120","author":"Bhol","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/clim.2000.4845","article-title":"Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice","volume":"95","author":"Lazarova","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope spreading: lessons from autoimmune skin diseases","volume":"110","author":"Chan","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0040","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jama.1991.03470110089038","article-title":"Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome","volume":"266","author":"Chan","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0045","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/00003226-199809000-00007","article-title":"The association between ocular cicatricial pemphigoid and rheumatoid arthritis","volume":"17","author":"Olsen","year":"1998","journal-title":"Cornea"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1523-1747.ep12292578","article-title":"Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid","volume":"108","author":"Chan","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1079-2104(98)90395-X","article-title":"Oral pemphigoid. Subset of cicatricial pemphigoid?","volume":"85","author":"Mobini","year":"1998","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0060","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1073\/pnas.88.24.11579","article-title":"Association of DQw7 (DQB1\u204e0301) with ocular cicatricial pemphigoid","volume":"88","author":"Ahmed","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1523-1747.ep12332352","article-title":"Significantly increased occurrence of HLA-DQB1\u204e0301 allele in patients with ocular cicatricial pemphigoid","volume":"108","author":"Chan","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2001.04380.x","article-title":"Mucous membrane pemphigoid: HLA-DQB1\u204e0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production","volume":"145","author":"Setterfield","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0075","series-title":"Blistering skin diseases","first-page":"56","author":"Chan","year":"2009"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00347-008-1699-x","article-title":"Mucous membrane pemphigoid with ocular involvement. Part I. Clinical manifestations, pathogenesis, and diagnosis","volume":"105","author":"Schmidt","year":"2008","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s003470050021","article-title":"Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications","volume":"97","author":"Messmer","year":"2000","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0090","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-epiligrin cicatricial pemphigoid and relative risk for cancer","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0095","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2340\/00015555-0560","article-title":"Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab","volume":"89","author":"Schumann","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bjo.2007.129510","article-title":"The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement","volume":"93","author":"Ross","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0110","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/09273941003682300","article-title":"Keratoprothesis in autoimmune disease","volume":"18","author":"Ciralsky","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08820530590931368","article-title":"Cicatricial pemphigoid and dry eye","volume":"20","author":"Dart","year":"2005","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0714.2006.00483.x","article-title":"Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin","volume":"36","author":"Malik","year":"2007","journal-title":"J Oral Path Med"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0125","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2230.2007.02463.x","article-title":"Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to beta4 integrin subunit","volume":"32","author":"Letko","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0130","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1167\/iovs.08-3345","article-title":"Tumor necrosis factor-alpha in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts","volume":"50","author":"Saw","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept","volume":"46","author":"Sacher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0140","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.007_bb0145","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.eye.6702948","article-title":"Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha","volume":"21","author":"John","year":"2007","journal-title":"Eye (London)"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T02:56:56Z","timestamp":1543373816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X11000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0738081X11000836"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.007","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}